{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:13:32Z","timestamp":1790936012861,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This report summarizes information on drugs recently approved by the Food and Drug Administration, Office of Drug Evaluation I, Division of Oncology Drug Products. Five applications supporting new claims will be discussed: Trisenox\u2122 (arsenic trioxide) for induction of remission and consolidation in patients with acute promyelocytic leukemia who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose disease is characterized by the presence of the t(15;17) translocation or PML\/RAR-alpha gene expression; Nolvadex\u00ae (tamoxifen citrate) in women with ductal carcinoma in situ, following breast surgery and radiation, to reduce the risk of invasive breast cancer; Arimidex\u00ae (anastrazole) for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer; Taxol\u00ae (paclitaxel), 175 mg\/m2 by 3 h infusion in combination with cisplatin for first-line treatment of advanced ovarian cancer; and Targretin\u00ae gel (bexarotene) for the topical treatment of cutaneous lesions in patients with stage IA and IB cutaneous T-cell lymphoma who have not tolerated other therapies or who have refractory or persistent disease.<\/jats:p><jats:p>Information provided includes rationale for drug development, study design, efficacy and safety results, and pertinent literature references.<\/jats:p>","DOI":"10.1634\/theoncologist.6-1-4","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"4-11","source":"Crossref","is-referenced-by-count":81,"title":["Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene"],"prefix":"10.1093","volume":"6","author":[{"given":"Martin H.","family":"Cohen","sequence":"first","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hirschfeld","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Flamm","family":"Honig","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"O'Leary","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"White","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2001,2,1]]},"reference":[{"key":"2021122210045691700_R1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000239130","article-title":"Pharmacokinetic properties of the trypanocidal drug melarsoprol","volume":"39","author":"Burri","year":"1993","journal-title":"Chemotherapy"},{"key":"2021122210045691700_R2","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients","volume":"89","author":"Shen","year":"1997","journal-title":"Blood"},{"key":"2021122210045691700_R3","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","article-title":"Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide","volume":"339","author":"Soignet","year":"1998","journal-title":"New Engl J Med"},{"key":"2021122210045691700_R4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1056\/NEJM199307153290307","article-title":"Medical progress: acute promyelocytic leukemia","volume":"329","author":"Warrell","year":"1993","journal-title":"New Engl J Med"},{"key":"2021122210045691700_R5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V78.6.1413.1413","article-title":"A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients","volume":"78","author":"Chen","year":"1991","journal-title":"Blood"},{"issue":"suppl 1","key":"2021122210045691700_R6","first-page":"S37","article-title":"Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond","volume":"12","author":"Tallman","year":"1998","journal-title":"Leukemia"},{"key":"2021122210045691700_R7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.7326\/0003-4819-127-11-199712010-00013","article-title":"Ductal carcinoma in situ of the breast","volume":"127","author":"Fonseca","year":"1997","journal-title":"Ann Intern Med"},{"key":"2021122210045691700_R8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/bmj.317.7160.734","article-title":"Ductal carcinoma in situ of the breast","volume":"317","author":"Silverstein","year":"1998","journal-title":"Br Med J"},{"key":"2021122210045691700_R9","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199306033282201","article-title":"Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122210045691700_R10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y","article-title":"Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma","volume":"86","author":"Fisher","year":"1999","journal-title":"Cancer"},{"key":"2021122210045691700_R11","first-page":"271","volume-title":"Ductal Carcinoma In Situ of the Breast","author":"Silverstein","year":"1997"},{"key":"2021122210045691700_R12","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2021122210045691700_R13","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"key":"2021122210045691700_R14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00002018-199921040-00005","article-title":"Risks and benefits of aromatase inhibitors in postmenopausal breast cancer","volume":"21","author":"Michaud","year":"1999","journal-title":"Drug Saf"},{"key":"2021122210045691700_R15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1677\/erc.0.0060187","article-title":"Biology of aromatase inhibitors: pharmacology\/endocrinology within the breast","volume":"6","author":"Miller","year":"1999","journal-title":"Endocr Relat Cancer"},{"key":"2021122210045691700_R16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1677\/erc.0.0060075","article-title":"Use of aromatase inhibitors in breast cancer","volume":"6","author":"Santen","year":"1999","journal-title":"Endocr Relat Cancer"},{"key":"2021122210045691700_R17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"New Engl J Med"},{"key":"2021122210045691700_R18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.1996.0210","article-title":"Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity","volume":"62","author":"Connelly","year":"1996","journal-title":"Gynecol Oncol"},{"key":"2021122210045691700_R19","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.1997.15.5.1965","article-title":"Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose limiting","volume":"15","author":"Gordon","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122210045691700_R20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","article-title":"Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology","volume":"260","author":"Weinstock","year":"1988","journal-title":"JAMA"},{"key":"2021122210045691700_R21","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0889-8588(18)30057-1","article-title":"Topical treatment of early cutaneous T-cell lymphoma","volume":"9","author":"Ramsay","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122210045691700_R22","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0889-8588(18)30063-7","article-title":"Experimental therapies in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Foss","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122210045691700_R23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0733-8635(05)70155-8","article-title":"Emerging new therapies for cutaneous T-cell lymphoma","volume":"18","author":"Duvic","year":"2000","journal-title":"Dermatol Clin"},{"key":"2021122210045691700_R24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2165\/00003495-199753030-00003","article-title":"Current use and future potential role of retinoids in dermatology","volume":"53","author":"Orfanos","year":"1997","journal-title":"Drugs"},{"key":"2021122210045691700_R25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2340\/0001555567232236","article-title":"Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate\u2014a study from the Scandinavian Mycosis Fungoides Group","volume":"67","author":"Molin","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"2021122210045691700_R26","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1997.15.2.790","article-title":"Initial clinical trial of a selective retinoid X receptor ligand LGD1069","volume":"15","author":"Miller","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.6-1-4","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.6-1-4","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/1\/4\/41837613\/oncolo_6_1_4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/1\/4\/41837613\/oncolo_6_1_4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T06:55:46Z","timestamp":1705215346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/6\/1\/4\/6387686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2001,2,1]]},"published-print":{"date-parts":[[2001,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.6-1-4","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2001,2,1]]},"published":{"date-parts":[[2001,2,1]]}}}